Event-Driven Stocks

Nurix Therapeutics, Inc.

NRIXNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 4 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$84.0M$54.5M$77.0M$38.6M$29.8M$17.8M
Operating income−$285.7M−$213.0M−$155.1M−$183.9M−$117.9M−$65.0M
Net income−$264.5M−$193.6M−$143.9M−$180.4M−$117.2M−$43.2M
Total assets$688.1M$669.3M$355.6M$416.8M$476.8M$396.3M
Total liabilities$149.4M$142.3M$155.1M$113.1M$134.5M$106.1M
Equity$538.7M$527.0M$200.5M$303.7M$342.3M$290.3M
EPS (diluted)$-3.05$-2.88$-2.65$-3.71$-2.73—
Shares out.75.9M48.9M47.3M44.7M38.9M38.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−340.2%
Net margin
−314.9%
Return on equity
−49.1%
Return on assets
−38.4%
Return on capital (ROCE)
−47.5%
Liabilities / assets
21.7%
Debt / equity
0.28×
Book value / share
$7.10
Revenue growth (YoY)
54.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
1.20grey zone
Accruals / assets
−2.2%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
55
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 4 warning● 3 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Altman Z″ in the grey zone
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202618.6M22.2-3.0%
Apr 30, 202619.2M24.30.0%
Apr 15, 202619.2M14.1+5.9%
Mar 31, 202618.1M11.6+12.1%
Mar 13, 202616.2M19.6+1.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)